Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Enveric Biosciences, Inc. (ENVB)

Enveric Biosciences Q2 2026 net loss widens to $3.0 million; cash $8.3 million

Negative Impact 3 of 5 earnings Written later

Enveric Biosciences reported a second-quarter 2026 net loss of $3.0 million, up from $2.5 million a year earlier, and cash on hand of $8.3 million as of June 30, 2026. The company also gave an update on its lead drug candidate EB-003, including preclinical data and the start of genotoxicity studies ahead of a planned IND submission.

Key points

  • Net loss attributable to stockholders was $3.0 million for the quarter ended June 30, 2026, versus $2.5 million a year earlier.
  • Basic and diluted loss per share was $0.76, compared with $11.65 in the second quarter of 2025.
  • The company raised $5.0 million in gross offering proceeds and $1.5 million from warrant exercises in the quarter.
  • Genotoxicity studies for EB-003 were initiated, a step the filing describes as required for IND submission.

The filing

CompanyEnveric Biosciences, Inc. (ENVB)
Form8-K, current report
Filed with the SECAug 14, 2026, 4:15 PM ET
Accession number0001493152-26-038385

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.